Follow
"Immune checkpoint inhibitors such as pembrolizumab or nivolumab, which inhibit PD-1, have greatly improved survival for many patients with cancer, but are prohibitively expensive and unattainable for most of the global cancer population. Optimized dosing, with a reduced unit dose, less frequent schedule and/or shorter duration of treatment could reduce costs and potentially toxicity, thereby improving global access to effective cancer therapy."
